MarketCapExport financials
Cytosorbents Corporation (CTSO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Cytosorbents Corporation CTSO
$ 4.3
1.63%
Facebook
X
Telegram
Cytosorbents Corporation Financial Ratios 2025-1997 | CTSO
Brief overview of Cytosorbents Corporation's multiples and efficiency
The review covers five available annual periods spanning 2021 to 2025.
The latest available valuation ratios are P/S 0.94x (median 1.53x), P/B 5.9x (median 4.45x). Current valuation broadly matches recent historical reference points; the difference from five-year medians is -2.9%.
Returns on assets and capital are represented by ROE -138.9%, ROA -18.6%, ROCE -2.5%. Current return ratios are negative, materially weakening the fundamental profile.
The PEG ratio is 7.39x; investors pay a high price per unit of expected growth.
The time from paying for inputs to receiving cash fell from 210.1 days to 104.4 days. Cash turnover improved.
Valuation takeaway
Cytosorbents Corporation's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.
Annual Financial Ratios Cytosorbents Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-4.3 | -2.6 | -1.5 | -4.8 | -6.6 | -52.0 | -8.3 | -13.2 | -24.8 | -11.8 | -11.8 | -12.4 | -14.1 | -5.7 | -4.4 | -73.9 | - | - | - | - | - | - | - | - | - | - | - | - | - |
P/S |
0.9 | 1.5 | 1.4 | 16.8 | 15.0 | 34.1 | 6.4 | 10.1 | 13.9 | 14.8 | 19.9 | 28.0 | 27.3 | 15.5 | 661.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-0.1 | -0.4 | -0.7 | -0.0 | -0.2 | -0.2 | -0.6 | -0.6 | -0.3 | -0.5 | -0.3 | -1.3 | -0.0 | -0.0 | -0.1 | -0.1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EV (Enterprise Value) |
66.9 M | 87.4 M | 60 M | 163 M | 136 M | 347 M | 172 M | 220 M | 206 M | 146 M | 93.3 M | 116 M | 82.2 M | 34 M | 24.5 M | 216 M | -1.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.22 | -0.28 | -0.68 | -0.13 | -0.2 | -0.05 | -0.57 | -0.495 | -0.349 | -0.445 | -0.369 | -0.502 | -0.492 | -0.433 | -0.686 | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
-4.9 | -5.8 | -2.0 | -29.8 | -4.8 | -34.8 | -8.9 | -14.1 | -21.0 | -12.4 | -9.8 | -15.5 | -14.1 | -5.8 | -5.3 | -77.0 | - | - | - | - | - | - | - | - | - | - | - | - | - |
PEG |
-0.03 | -0.02 | -0.01 | -0.1 | -0.13 | 7.39 | 1.16 | 0.18 | -0.78 | 0.28 | -0.16 | 0.17 | 6.92 | -0.14 | 1.45 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
P/B |
5.9 | 4.9 | 1.9 | 4.4 | 2.6 | 5.1 | 46.8 | 13.4 | 20.4 | -297.7 | 11.6 | 29.1 | -4.6 | -1.8 | 75.0 | -443.6 | - | - | - | - | - | - | - | - | - | - | - | - | - |
P/CF |
-2.8 | -3.8 | -2.1 | -5.6 | -11.5 | -72.5 | -8.8 | -18.4 | -25.8 | -19.3 | -9.9 | -16.4 | -17.8 | -5.7 | -6.2 | -86.8 | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-138.88 | -186.54 | -124.56 | -92.76 | -39.24 | -9.89 | -563.65 | -101.63 | -82.44 | 2518.28 | -99.04 | -235.21 | 32.79 | 31.51 | -1721.93 | 36.07 | 47.66 | 90.20 | 3212.73 | -3246.54 | 37.56 | 15.74 | 153.80 | 271.35 | -660.85 | -57.42 | -10695.26 | -118.18 | -598.99 |
ROA % |
-18.56 | -43.74 | -55.23 | -51.89 | -27.43 | -8.71 | -70.36 | -52.56 | -35.10 | -123.16 | -72.25 | -110.07 | -115.62 | -109.71 | -258.26 | -160.54 | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-249.86 | -148.12 | -136.07 | -17.97 | -15.28 | -3.33 | -108.76 | -59.46 | -60.55 | -318.85 | -113.31 | -183.66 | -480.55 | -276.46 | -746.19 | 40.41 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.2 | 1.3 | 1.8 | 2.3 | 3.3 | 8.4 | 2.1 | 4.3 | 2.6 | 1.3 | 3.2 | 1.7 | 1.1 | 1.4 | 1.1 | 0.8 | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
73.2 | 68.6 | 68.8 | 198.0 | 163.9 | 146.9 | 65.4 | 64.0 | 53.1 | 54.9 | 49.4 | 72.5 | 68.3 | 14.1 | 365.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
138.3 | 104.1 | 136.6 | 107.6 | 122.9 | 79.1 | 104.8 | 40.6 | 52.6 | 77.0 | 196.4 | 92.0 | 46.9 | 780.0 | 13377.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
107.2 | 121.7 | 109.1 | 58.3 | 76.7 | 64.0 | 132.3 | 95.8 | 103.6 | 122.8 | 112.9 | 119.4 | 150.2 | 915.3 | 20955.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
211.6 | 172.7 | 205.5 | 305.6 | 286.8 | 226.0 | 170.1 | 104.6 | 105.8 | 131.9 | 245.9 | 164.5 | 115.1 | 794.1 | 13742.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
104.4 | 51.0 | 96.4 | 247.3 | 210.1 | 162.0 | 37.9 | 8.8 | 2.1 | 9.1 | 132.9 | 45.0 | -35.0 | -121.2 | -7212.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Cytosorbents Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.07 | -0.08 | -0.05 | 0.03 | -0.02 | - | -0.05 | -0.08 | -0.11 | - | -0.21 | -0.14 | -0.17 | - | -0.28 | -0.25 | -0.21 | -0.25 | -0.15 | -0.11 | -0.1 | - | -0.02 | -0.08 | -0.1 | -0.13 | -0.21 | -0.11 | -0.15 | -0.17 | -0.1 | -0.19 | -0.1 | -0.12 | -0.07 | -0.07 | -0.06 | -0.19 | -0.09 | -0.12 | -0.07 | -0.08 | -0.11 | 0.06 | -0.19 | -0.84 | -0.22 | -0.27 | -0.2 | - | -0.01 | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 |
EBITDA per Share |
-0.03 | -0.04 | -0.04 | - | -0.06 | - | -0.08 | - | -0.08 | - | - | - | -0.17 | - | -0.19 | -0.19 | -0.17 | -0.22 | -0.11 | -0.11 | -0.06 | -0.06 | -0.04 | -0.08 | -0.07 | -0.17 | -0.16 | -0.1 | -0.13 | -0.18 | -0.08 | -0.13 | -0.1 | -0.13 | -0.07 | -0.08 | -0.06 | -0.18 | -0.08 | -0.1 | -0.08 | -0.09 | -0.08 | -0.09 | -0.11 | -0.12 | -0.11 | -0.11 | -0.11 | - | - | -0.01 | -0.01 | - | - | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 |
ROE % |
336.04 | -262.28 | -49.19 | -38.68 | -86.51 | -76.34 | -126.01 | -130.86 | -131.52 | -100.50 | -131.67 | -104.88 | -95.52 | -70.22 | -85.10 | -63.00 | -46.41 | -35.63 | -21.61 | -13.60 | -10.93 | -9.89 | -124.58 | -324.96 | -425.12 | -563.65 | -480.01 | -296.32 | -226.91 | -101.63 | -100.39 | -102.66 | -85.19 | -82.44 | -418.59 | -562.18 | 88.62 | 490.81 | 831.94 | 960.87 | 344.43 | -100.35 | -225.73 | -228.86 | -293.10 | -260.25 | -102.42 | -54.69 | 3.50 | 28.10 | 33.71 | 35.96 | 38.31 | 26.89 | -516.21 | -943.12 | -1333.66 | -1345.94 | -543.10 | -421.30 | -381.53 |
ROA % |
-27.15 | -18.43 | -11.57 | -12.68 | -29.67 | -26.76 | -46.09 | -52.03 | -56.74 | -43.81 | -63.40 | -54.84 | -53.51 | -40.76 | -47.50 | -27.90 | -32.67 | -26.66 | -17.02 | -11.21 | -9.64 | -8.71 | -22.38 | -46.59 | -56.36 | -70.36 | -71.73 | -55.38 | -59.45 | -50.33 | -47.59 | -47.32 | -37.50 | -35.10 | -72.66 | -86.70 | -110.51 | -123.13 | -94.99 | -97.72 | -53.97 | -76.94 | -178.35 | -170.75 | -205.38 | -174.98 | -74.94 | -92.22 | -110.60 | -99.09 | -118.61 | -126.12 | -133.87 | -93.61 | -175.06 | -218.73 | -244.59 | -201.87 | -81.46 | -63.19 | -57.22 |
ROCE % |
149.59 | -228.40 | -125.75 | -114.51 | -107.03 | -80.30 | -120.00 | -111.14 | -117.91 | -94.18 | -117.22 | -95.09 | -81.92 | -54.67 | -69.95 | -54.56 | -43.61 | -33.25 | -21.29 | -16.11 | -13.65 | -13.09 | -168.67 | -330.84 | -432.87 | -555.12 | -429.19 | -280.56 | -199.09 | -92.03 | -96.13 | -101.06 | -99.04 | -95.91 | -400.55 | -539.93 | 49.63 | 505.67 | 824.91 | 959.04 | 365.06 | -108.83 | -127.98 | -139.23 | -146.50 | -142.60 | -94.79 | -47.49 | -3.12 | 26.00 | 31.17 | 33.69 | 33.01 | 23.04 | -183.10 | -375.66 | -574.13 | -583.31 | -206.14 | -187.38 | -189.79 |
Current Ratio |
1.0 | 1.1 | 1.2 | 1.3 | 1.4 | 1.3 | 1.4 | 1.5 | 1.7 | 1.8 | 1.6 | 1.9 | 2.0 | 2.3 | 2.7 | - | 3.0 | 3.3 | 3.9 | 4.1 | 8.6 | 8.4 | 8.4 | 8.4 | 8.4 | 1.1 | 1.1 | 1.1 | 1.1 | 2.0 | 2.0 | 2.0 | 2.0 | 1.7 | 1.7 | 1.7 | 1.7 | 1.2 | 1.2 | 0.9 | 0.9 | 3.7 | 3.7 | 3.7 | - | - | - | - | - | 1.3 | 1.3 | 1.9 | 4.1 | 1.6 | 1.6 | 1.6 | 1.6 | 1.2 | 1.2 | 1.2 | 1.2 |
DSO |
66.0 | 75.0 | 73.0 | 73.1 | 78.4 | - | 76.6 | 75.3 | 65.1 | - | 68.4 | 60.8 | 54.0 | - | 27.9 | 24.6 | 47.8 | 41.3 | 51.4 | 40.9 | 43.8 | 39.4 | 44.6 | 48.1 | 50.4 | 54.9 | 66.9 | 65.4 | 73.9 | 59.2 | 62.6 | 62.5 | 57.0 | 43.3 | 52.6 | 56.4 | 53.3 | 42.4 | 54.2 | 58.9 | 52.5 | 33.6 | 39.0 | 55.5 | 94.1 | 72.1 | 35.0 | 51.2 | 54.6 | - | 46.9 | 141.8 | 62.0 | - | 7.8 | 56.9 | 79.8 | - | - | - | - |
DIO |
144.2 | 141.6 | 124.8 | 109.5 | 104.2 | - | 102.8 | 157.1 | 160.0 | - | 71.5 | 50.6 | 59.2 | - | 36.0 | 70.0 | 204.6 | - | 152.2 | 114.4 | 95.9 | - | 84.4 | 75.1 | 91.6 | - | 113.7 | 105.2 | 77.3 | - | 37.0 | 42.6 | 47.4 | - | 47.9 | 49.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
90.7 | 102.9 | 104.0 | 109.4 | 120.7 | - | 73.2 | 106.2 | 133.7 | - | 89.4 | 78.2 | 53.1 | - | 23.8 | 62.0 | 152.9 | - | 102.3 | 64.7 | 58.2 | - | 57.9 | 51.5 | 74.1 | - | 109.7 | 101.4 | 92.5 | - | 66.0 | 75.9 | 79.5 | - | 74.9 | 76.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 197.8 | 182.6 | 182.5 | - | 179.4 | 232.4 | 225.1 | - | 139.9 | 111.4 | 113.3 | - | 63.9 | 94.5 | 252.3 | 41.3 | 203.6 | 155.3 | 139.7 | 39.4 | 129.1 | 123.1 | 142.0 | 54.9 | 180.6 | 170.6 | 151.2 | 59.2 | 99.7 | 105.1 | 104.4 | 43.3 | 100.5 | 105.4 | 53.3 | 42.4 | 54.2 | 58.9 | 52.5 | 33.6 | 39.0 | 55.5 | 94.1 | 72.1 | 35.0 | 51.2 | 54.6 | - | 46.9 | 141.8 | 62.0 | - | 7.8 | 56.9 | 79.8 | - | - | - | - |
Cash Conversion Cycle |
- | - | 93.7 | 73.3 | 61.8 | - | 106.2 | 126.2 | 91.3 | - | 50.5 | 33.2 | 60.2 | - | 40.0 | 32.5 | 99.5 | 41.3 | 101.3 | 90.6 | 81.4 | 39.4 | 71.1 | 71.6 | 67.9 | 54.9 | 70.9 | 69.1 | 58.7 | 59.2 | 33.6 | 29.2 | 24.9 | 43.3 | 25.6 | 28.8 | 53.3 | 42.4 | 54.2 | 58.9 | 52.5 | 33.6 | 39.0 | 55.5 | 94.1 | 72.1 | 35.0 | 51.2 | 54.6 | - | 46.9 | 141.8 | 62.0 | - | 7.8 | 56.9 | 79.8 | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Cytosorbents Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Conformis
CFMS
|
- | - | $ 16.4 M |  USA |
 |
Bruker Corporation
BRKR
|
$ 64.0 | 7.26 % | $ 9.72 B | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 0.06 % | $ 66.1 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.7 | 0.06 % | $ 634 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.61 | 13.03 % | $ 414 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.18 | 3.31 % | $ 1.4 B | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
$ 16.08 | 0.75 % | $ 576 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Electromed
ELMD
|
$ 27.86 | 1.05 % | $ 230 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 65.58 | 3.69 % | $ 1.94 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 85.73 | 0.32 % | $ 50.1 B | USA |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
AdaptHealth Corp.
AHCO
|
$ 5.57 | 0.43 % | $ 753 M | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.9 | 0.69 % | $ 63.9 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 15.88 | 2.25 % | $ 1.22 B | USA |
 |
Inogen
INGN
|
$ 5.23 | 2.75 % | $ 139 M | USA |
 |
InMode Ltd.
INMD
|
$ 14.19 | 0.21 % | $ 917 M | Israel |
 |
Inspire Medical Systems
INSP
|
$ 68.81 | 0.59 % | $ 2.02 B | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 2.51 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 85.2 | 0.08 % | $ 1.08 B | USA |
 |
AxoGen
AXGN
|
$ 43.32 | 0.48 % | $ 1.99 B | USA |
 |
Align Technology
ALGN
|
$ 145.63 | 4.36 % | $ 10.6 B | USA |
|
LENSAR
LNSR
|
$ 7.08 | 0.28 % | $ 84.7 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Medtronic PLC
MDT
|
$ 88.51 | 0.32 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.71 | 0.1 % | $ 696 M | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Myomo
MYO
|
$ 1.67 | 1.83 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.66 | 0.45 % | $ 42.8 M | Israel |
 |
InspireMD
NSPR
|
$ 0.7 | 0.37 % | $ 45 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.16 | 0.11 % | $ 363 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.13 | 1.29 % | $ 47.6 K | USA |
 |
Insulet Corporation
PODD
|
$ 135.78 | 0.01 % | $ 9.55 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.6 | 1.66 % | $ 169 M | Canada |
 |
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M | Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.18 | 0.63 % | $ 136 M | USA |
 |
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | USA |
 |
AVITA Medical
RCEL
|
$ 11.58 | 5.75 % | $ 323 M |  Australia |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
$ 2.83 | 1.37 % | $ 116 M | USA |
 |
Sintx Technologies
SINT
|
$ 1.87 | 5.06 % | $ 5.19 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.22 | 0.4 % | $ 27 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.68 | 0.02 % | $ 23.1 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |